遗传代谢性肝病的诊治

张亚南; 许影; 蒋畅; 高沿航

doi:10.3969/j.issn.1001-5256.2019.04.048

遗传代谢性肝病的诊治

DOI: 10.3969/j.issn.1001-5256.2019.04.048

吉林大学白求恩第一医院肝胆胰内科

基金项目:

国家重点研发计划“精准医学研究”重点专项(2017YFC0908100)；国家艾滋病和病毒性肝炎等重大传染病防治专项(2017ZX10202202)；吉林省科技发展计划项目(20160101097jc)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1720
- HTML全文浏览量: 50
- PDF下载量: 560
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Diagnosis and treatment of inherited metabolic liver disease

Department of Hepatology, The First Hospital of Jilin University

Research funding:

摘要

摘要: 肝脏是大多数代谢途径的关键场所,因此在遗传代谢性疾病中肝脏一般最早被累及且损伤最重,某些遗传代谢性疾病的肝脏损伤甚至会发展为肝硬化甚至肝脏的恶性肿瘤,预后较差。遗传代谢性肝病临床表现复杂,常规诊断和治疗方法局限,是临床医生面临的棘手问题。随着细胞和分子生物学技术的发展,新的诊疗手段,如基因检测、基因治疗、干细胞移植等已逐步开展临床应用,为难治性患者带来希望。就肝豆状核变性、遗传性血色病、糖原累积病、α1-抗胰蛋白酶缺乏症、遗传性高胆红素血症、遗传性胆汁淤积等相对常见的遗传代谢性肝病的诊治进展作一综述。
- 肝疾病 /
- 代谢疾病 /
- 诊断 /
- 治疗学 /
- 综述
Abstract: The liver is the key place for most metabolic pathways, so it is often involved earliest and has the most severe injury, and liver injury of some inherited metabolic diseases may develop into liver cirrhosis and even malignant tumors of the liver and tended to have poor prognosis. Inherited metabolic liver disease often has complicated clinical manifestations, and the limitations of conventional diagnostic and therapeutic methods are difficult issues for clinical physicians. With the development of cellular and molecular biology techniques, new diagnostic and therapeutic methods, such as gene detection, gene therapy, and stem cell transplantation, have been gradually applied in clinical practice, bringing hope to patients with refractory diseases. This article reviews the recent advances in the diagnosis and treatment of inherited metabolic liver diseases commonly seen in clinical practice, such as hepatolenticular degeneration, hereditary hemochromatosis, glycogen storage disease, ɑ1-antitrypsin deficiency, hereditary hyperbilirubinemia, and hereditary cholestasis.
- liver diseases /
- metabolic diseases /
- diagnosis /
- therapeutics /
- review

HTML全文

参考文献(34)

[1]TAYLOR E, CAITLIN M, HUDSON P, et al. Nuclease-mediated gene therapies for inherited metabolic diseases of the liver[J]. Yale J Biol Med, 2017, 90 (4) :553-566.

[2] HU YM, JIANG ZF, ZHU FT. Practical pediatrics[M]. 8 th.Beijing:People's Medical Publishing House, 2012:2249-2336. (in Chinese) 胡亚美, 江载芳.诸福棠.实用儿科学[M]. 8版.北京:人民卫生出版社, 2012:2249-2336.

[3]OLIVER B, KARL H, STEPHEN G. Wilson's disease and other neurological copper disorders[J]. Lancet Neurol, 2015, 14 (1) :103-113.

[4]STENSON P, MATTHEW M, EDWARD V, et al. The Human Gene Mutation Database:Towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies[J]. Hum Genet, 2017, 136 (6) :665-677.

[5] COFFEY AJ, DURKIE M, HAGUE S, et al. A genetic study of Wilson's disease in the United Kingdom[J]. Brain, 2013, 136 (5) :1476-1487.

[6]CHENG N, WANG K, HU WB, et al. Wilson disease in the South chinese han population[J]. Can J Neurol Sci, 2014, 41:363-367.

[7]AGGARWAL A, BHATT M. Advances in treatment of Wilson disease[J]. Tremor Other Hyperkinet Mov (N Y) , 2018, 8:525.

[8]CZLONKOWSKA A, LITWIN T, DUSEK P, et al. Wilson disease[J]. Nat Rev Dis Primers, 2018, 4 (1) :21.

[9]POWEL LW, SECKINGTON RC, DEUGNIER Y. Haemochromatosis[J]. Lancet, 2016, 388:706-716.

[10]WALLACE DF, SUBRAMANIAM VN. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of nest-generation sequencing data[J]. Genet Med, 2016, 18 (6) :618-626.

[11]GROSSE SD, GURRIN LC, BERTALLI NA, et al. Clinical penetrance in hereditary hemochromatosis:Estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes[J]. Genet Med, 2018, 20 (4) :383-389.

[12]RICKY J, MAYA S, ERICA M, et al. Functional consequences of transferrin receptor-2 mutations causing hereditary hemochromatosis type3[J]. Mol Genet Genomic Med, 2015, 3 (3) :221-232.

[13]DOROTHEA B, SUNDRELA KM, JULIAN KM, et al. Efficacy and safety of erythrocytapheresis and low-dose erythropoietin for treatment of hemochromatosis[J]. J Clin Apheresis, 2017, 32 (3) :170-174.

[14]OLDFORS A, DIMAURO S. New insights in the field of muscle glycogenoses[J]. Curr Opin Neurol, 2013, 26 (5) :544-553.

[15]STONE WL, ADIL A. Glycogen storage disease[J]. Treasure Island (FL) :Stat Pearls Publishing, 2019.

[16]CHOU JY, KIM GY, CHO JH. Recent development and gene therapy for glycogen storage disease type Ia[J]. Liver Res, 2017, 1 (3) :174-180.

[17]CRAIG TJ. Suspecting and testing for alpha-1 antitrypsin deficiency-an allergist's and/or immunologist's perspective[J]. J Allergy Clin Immunol Pract, 2015, 3 (4) :506-511.

[18]DUVOIX A, ROUSSEL BD, LOMAS DA. Molecular pathogenesis of alpha-1-antitrypsin deficiency[J]. Rev Mal Respir, 2014, 31 (10) :992-1002.

[19]LASCANO JE, CAMPOS MA. The important role of primary care providers in the detection of alpha-1-antitrypsin deficiency[J]. Postgrad Med, 2017, 129 (8) :889-895.

[20]GREULICH T, VOGELMEIER CF. Alpha-1-antitrypsin deficiency:Increasing awareness and improving diagnosis[J]. Ther Adv Respir Dis, 2016, 10 (1) :72-84.

[21]GOOPTU B, DICKENS JA, LOMAS DA. The molecular and cellular pathology ofα1-antitrypsin deficiency[J]. Trends Mol Med, 2014, 20:116-127.

[22]GRUNTMAN AM, FLOTTE TR. Therapeutics:Gene therapy for alpha-1-antitrypsin deficiency[J]. Methods Mol Biol, 2017, 1639:267-275.

[23]THOGULUVA C, JOHN S. Gilbert syndrome[J]. Treasure Island (FL) :Stat Pearls Publishing, 2018.

[24]MARUO Y, NAKAHARA S, YANAGI T, et al. Genotype of UGT1A1and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome[J]. J Gastroenterol Hepatol, 2016, 31 (2) :403-408.

[25]EBRAHIMI A, RAHIM F. Crigler-Najjar syndrome:Current perspectives and the application of clinical genetics[J]. Endocr Metab Immune Disord Drug Targets, 2018, 18 (3) :201-211.

[26] LEE J, CHEN H, NI Y, et al. Neonatal Dubin-Johnson syndrome:Long term follow-up and MRP2 mutations study[J].Pediatr Res, 2006, 59 (4) :584-589.

[27]MEMON N, WEINBERGER BI, HEGYI T, et al. Inherited disorders of bilirubin clearance[J]. Pediatr Res, 2016, 79 (3) :378-386.

[28]STRASSBURG CP. Hyperbilirubinemia syndromes (GilbertMeulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome) [J]. Best Pract Res Clin Gastroenterol, 2010, 24:555-571.

[29]JACQUEMIN E. Progressive familial intrahepatic cholestasis[J]. Clin Res Hepatol Gas, 2012, 36 (1 Suppl) :s26-s35.

[30]TOGAWA T, SUGIURA T, ITO K, et al. Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next-generation sequencing[J]. J Pediatr, 2016, 171:171-177.

[31]CARIELLO M, PICCININ E, GARCIA-IRIGOYEN O, et al.Nuclear Receptor FXR, bile acids and liver damage:Introducing the progressive familial intrahepatic cholestasis with FXR mutations[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1308-1318.

[32]DROGE C, BONUS M, BAUMANN U, et al. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants[J].J Hepatol, 2017, 67 (6) :1253-1264.

[33]KRAWCZYK M, LIEBE R, WASILEWICZ M, et al. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch[J]. Liver Int, 2017, 37:743-747.

[34]HEGADE VS, KRAWCZYK M, KREMER AE, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus:A multicentre European study[J]. Aliment Pharmacol Ther, 2016, 43 (2) :294-302.

施引文献

资源附件(0)

访问统计